B of A Securities Raises GILD Price Target to $172

B of A Securities reiterated its Buy rating on Gilead Sciences, Inc. [GILD] and raised its price target from $168.00 to $172.00 on October 20, 2026. The research note outlines a bullish stance on the biopharmaceutical maker as the company approaches its next financial results report.

GILD Gilead Sciences, Inc.

$154.15 ▲ +29.05% year to date

1M 3M YTD

Daily close · Oct 19, 2026

B of A Securities's Call on Gilead Sciences

On October 20, 2026, the firm maintained its Buy rating while bumping up its expectations for the stock's future path from $168.00 to $172.00. This forward-looking opinion signals confidence in the drug maker's ongoing business drivers and treatment portfolio.

Other Institutional Activity in Gilead Sciences

ARS Wealth Advisors Group reported a holding of 1,458 shares worth about $217,280.

Gilead Sciences, Inc. Stock Down 2.0%

Gilead Sciences shares recently traded around $153.07 as of October 20, 2026, after closing at $153.07 on October 19. The stock trades above its 50-day moving average of $147.23 and its 200-day moving average of $138.18, sitting about 4.6% below its 52-week high of $160.51.

Recent Earnings

Gilead Sciences generated trailing-twelve-month revenue of $30.46 billion with a negative net margin of 10.6% and a trailing-twelve-month loss of $2.65 per share. The company is scheduled to release its next financial results on October 29, 2026.

Dividend

Gilead Sciences pays an annual dividend rate of $3.28 per share, which translates to a dividend yield of 2.14% with a payout ratio of 43.5%.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders executed several share sales prior to the analyst update. On September 15, 2026, officer Johanna Mercier sold 3,000 shares, and Chief Financial Officer Andrew D Dickinson sold 3,000 shares at $145.29 per share for $435,870. Later, on October 15, 2026, Mercier sold 3,000 shares under a planned arrangement at $156.22 for $468,660, while Dickinson also sold 3,000 shares in a planned transaction at $156.22 for $468,660.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the October update. Truist Securities maintained a Buy rating on October 7, 2026, lifting its target from $150.00 to $158.00. JP Morgan maintained an Overweight rating on October 7, 2026, raising its target from $160.00 to $170.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, moving its target from $123.00 to $126.00. Cantor Fitzgerald reiterated an Overweight rating with an unchanged target of $155.00 on October 8, 2026. Overall, the stock carries a consensus buy recommendation from 26 analysts with a mean price target of $160.15.

About Gilead Sciences, Inc.

Gilead Sciences discovers and delivers medical treatments for severe conditions, focusing heavily on HIV therapies like Biktarvy, Descovy, and Sunlenca alongside other antiviral medicines. The Foster City, California-based firm employs 17,000 people and serves patients across global healthcare markets.

Bottom Line

Investors will watch for upcoming earnings reports on October 29, 2026, to gauge whether the company's treatment revenue and margins match up with bullish Wall Street price targets.